PhD Scientific Days 2026

Theoretical and Translational Medicine 2.

Investigating the Efficacy and Safety of PI3K/AKT Pathway Inhibitors in Metastatic or Locally Advanced Breast Cancer with PIK3CA Mutations: A Systematic Review and Meta-Analysis

Előadó neve

Dr. Pallagi, Zsuzsanna

Neptune code

PN78DJ

Előadó munkahelye

Semmelweis University Centre for Translational Medicine

Előadó telefonszáma

+36203879630

Előadó e-mail címe

pzsuzsi5@gmail.com

Az előadás címe

Investigating the Efficacy and Safety of PI3K/AKT Pathway Inhibitors in Metastatic or Locally Advanced Breast Cancer with PIK3CA Mutations: A Systematic Review and Meta-Analysis

Szerző(k) neve és munkahelye

Dr. Zsuzsanna Pallagi¹, Prof. Dr. Dezső Csupor², Dr. Darius-Valentin Sandu¹, Prof. Dr. Zsuzsanna Kahán³, Mikolt Bakony¹, Dr. Sunaina Wadhwa⁴

1: Semmelweis University Centre for Translational Medicine
2: University of Szeged Institute of Clinical Pharmacy
3: University of Szeged, Albert Szent-Györgyi Health Centre, Department of Oncotherapy
4: Medical University of Vienna Department of Gynecologic Oncology

Bemutatás módja

Szóbeli

Szekció

Theoretical and Translational Medicine 2.

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction:
Breast cancer is one of the leading causes of death. The PI3K/AKT/mTOR signalling pathway is overactivated in approximately 50% of cases, and PIK3CA mutations can be detected in 40% of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancers, leading to increased resistance to standard therapies. The combination of PI3K/AKT inhibitors with endocrine therapy is considered a promising therapeutic option.
Aims:
We aim to assess the therapeutic value of PI3K/AKT inhibitors combined with endocrine therapy.
Methods:
We investigated the efficacy and safety of PI3K/AKT inhibitors in combination with endocrine therapy through a systematic review and meta-analysis. After submitting the PROSPERO protocol (CRD420251181854), we conducted a systematic search in PubMed, Embase, and CENTRAL databases. Title/abstract and full-text screening were performed independently by two investigators. Appropriate statistical methods were used to assess efficacy (progression-free survival, overall survival, clinical benefit, and objective response) and safety (adverse events, treatment discontinuation, and dose reduction). Risk of bias assessment was performed independently by two authors. The GRADE assessment was performed using the GRADEpro tool. The manuscript writing is currently ongoing.
Results:
The pooled hazard ratio for progression-free survival was 0.61 (95% CI, 0.52-0.73). Overall survival also showed improvement in the intervention group (HR: 0.73, 95% CI 0.50-1.08); however, the result was not statistically significant. The risk of developing severe hyperglycemia was higher in the intervention arm (RR 25.90, 95% CI, 11.85-56.59).
Conclusions:
The combination of PI3K/AKT inhibitors and endocrine therapy improved treatment efficacy in breast cancer with PIK3CA mutation. However, healthcare professionals should be aware of possible adverse events and appropriate strategies for managing them.
Funding:
Supported by the Semmelweis University Research Development and Innovation Fund.

University

Semmelweis University

Supervisor

Dezső Csupor

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

9767

Start

09:45

End

09:55